Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00096369 · ClinicalTrials.gov registry record · Phase 2
Tamoxifen in Preventing Breast Cancer in Women at Increased Risk for Breast Cancer
A Phase 2 study, sponsored by University of Texas Southwestern Medical Center.
- Terminated
- Registry status
- Phase 2
- Development phase
- 130
- Enrollment target
NCT00096369 is a Phase 2 study that was terminated before completion, run by University of Texas Southwestern Medical Center. The registered enrollment target is 130 participants.
The verdict
NCT00096369, a Phase 2 study, was terminated before completion, sponsored by University of Texas Southwestern Medical Center.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 130 participants
- Enrollment target
Study Summary
RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the development or recurrence of cancer. The use of tamoxifen may be effective in preventing breast cancer. PURPOSE: This randomized phase II trial is studying tamoxifen to see how well it works compared to placebo in preventing breast cancer in women who are at increased risk for the disease.
Interventions
- DRUG tamoxifen citrate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 130 participants |
| Start Date | 2000-02 |
| Est. Completion | 2007-03-15 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00096369
The ClinicalTrials.gov registry entry for NCT00096369 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 130 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Texas Southwestern Medical Center, which has 837 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which tamoxifen citrate is the first listed.
NCT00096369 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00096369 about?
NCT00096369 is a clinical study titled "Tamoxifen in Preventing Breast Cancer in Women at Increased Risk for Breast Cancer". RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the development or recurrence of cancer. The use of tamoxifen may be effective in preventing breast cancer. PURPOSE: This randomized phase II trial is studying tamoxifen to see how well it works compared to placebo in ...
What is the current status of trial NCT00096369?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 130 participants. The study started on 2000-02. Estimated completion is 2007-03-15.
What interventions are being tested in trial NCT00096369?
The interventions under investigation include: tamoxifen citrate (DRUG).
Who is sponsoring clinical trial NCT00096369?
This trial is sponsored by University of Texas Southwestern Medical Center, which has 837 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.